JPH0326170B2 - - Google Patents
Info
- Publication number
- JPH0326170B2 JPH0326170B2 JP58204243A JP20424383A JPH0326170B2 JP H0326170 B2 JPH0326170 B2 JP H0326170B2 JP 58204243 A JP58204243 A JP 58204243A JP 20424383 A JP20424383 A JP 20424383A JP H0326170 B2 JPH0326170 B2 JP H0326170B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- adsorbent
- column
- blood cells
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008280 blood Substances 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000003463 adsorbent Substances 0.000 claims description 30
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 description 28
- 239000002504 physiological saline solution Substances 0.000 description 13
- 210000001772 blood platelet Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 239000000306 component Substances 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 4
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930192878 garvin Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は血液中から白血球．血小板を吸着して
除去するための装置に関する。特に、成分輸血あ
るいは生化学検査のために、白血球・血小板を含
まない赤血球を得るための白血球および血小板除
去装置に関するものである。
従来、輸血においては全血を用いる場合が多か
つたが、最近は医療の進歩に併つていわゆる成分
輸血と呼ばれる必要な成分だけを輸血する治療法
が国内外において進められている。然るに赤血球
の成分輸血において、HL−Ａ型抗原を有する白
血球および血小板抗原を有する血小板を完全に除
去する優れた方法がないために、必ずしも赤血球
輸血が頻繁に行なわれているとは限らない。ま
た、赤血球の生化学的機能試験においても他の血
球成分の混在は良い結果をもたらさない。
輸血を目的とした赤血球の分画法の公知技術と
しては次のような方法がある。すなわち、(1)到立
遠心分離法、(2)生理食塩水洗浄法、(3)デキストラ
ンまたはHESによる赤血球沈降法、(4)ナイロン
カラム通過法、(5)解凍赤血球浮遊液の調製〔ブラ
ツド コンポーネント テエラピー，アメリカン
アソシエーシヨン オブ ブラツド バンクス
刊，ツウエンテイース センチエリー プレス
U.S.A.（Blood Component Therapy，
American Association oof Blood Banks，
Twentyth Century PressU.S.A），９−13頁
1969年；日本赤十字血液センター業務規準 昭和
50年：血球成分輸血時代要覧 大阪赤十字センタ
ー刊 昭和50年〕があり、この中で(3)は白血球除
去赤血球「日赤」として実際に行なわれている
が、いずれも赤血球の回収および白血球・血小板
の除去に関しては満足されるものではない。また
上記(4)の如き吸着体をカラムにつめて行なう方法
として木綿および木綿糸を用いる方法〔フレミン
グ（Fleming）、プリテイツシユ ジヤーナル
オブ エキスペリメンタルバソロジー（British
Journal of Experimental Pathalogy）、７巻281
頁、1926年；デイペンホルスト（Diepenhorst）
ら、ボツクス サイグニス（Vox Sang.）、23巻
308〜320頁、1972年〕、ダヌロン繊維を用いる方
法〔ラングフエルダー（Langfelder）ら、ボツ
クス サイグイニス（Vox Sang.）、19巻57頁，
1970年〕があるが、血小板や白血球の中のリンパ
球の分離が良好でないし、血液量に対し吸着体の
量が多く赤血球の回収が充分行なわれない。
中尾ら〔ネイチヤー ニユー バイオロジー
（Nature New Biology），246巻 94頁，1973
年〕はヘパリン加全血から陽イオン交換セルロー
スや陽イオン交換セフアデツクスを用いて赤血球
を純化しているが、イオン交換体が高価であり又
マグネシウムイオンが不可決であること、そし血
液量に対し吸着体の量が多い等の欠点があり実用
的でない。一方ライト（Wright）〔ザランセツト
（The Lancet），１巻４頁，1926年〕はろ紙に白
血球が吸着することをみとめているが、ガルビン
（Garvin）〔ジヤーナル オブ エキスペリメン
タル メデイシン（Journal of Experimental
Medicine），114巻51頁，1961年〕はろ紙に対す
る吸着はさほど大きくないとしている。
本発明者は上記の事情を鑑み鋭意研究した結
果、ヒト全血、赤血球沈層および哺乳動物の血液
からセルロース粉末、結晶セルロース、陰イオン
交換セルロースに殆んど完全に白血球・血小板を
付着せしめて赤血球を高純度、かつ高収率で回収
することに成功し本発明を完成するに至つた。
本発明の白血球および血小板除去装置は、カラ
ムと該カラム内に充填された吸着体を有する白血
球および血小板除去装置であつて、前記カラムは
血液流入口と血液流出口を有し、前記吸着体はセ
ルロース粉末、結晶セルロース、陰イオン交換セ
ルロースのうち少なくともひとつからなり、さら
に、前記カラム内には該吸着体を支持するメツシ
ユが設けられているものである。
本発明の実施において用いる血液としては、ヒ
ト新鮮血にヘパリン、ACD、CPD等の適当な抗
凝固剤を加えたものおよび赤血球沈層（日赤）で
あるが、必ずしもこれに限定されるものではなく
赤血球が浮遊した製剤ならなんでもよい。赤血球
沈層を用いる場合は、生理食塩水又は等張のバツ
フアーを1/3〜1/2容加えて用いる。
また、本発明の実施において用いる吸着体とし
ては、セルロース粉末、結晶セルロース、陰イオ
ン交換セルロースであり、例えば山陽国策パルプ
製KCフロツク、東洋ろ紙製ろ紙粉末、旭化成工
業製アビセル、ジエチルアミノエチルセルロース
などを挙げることができる。ジエチルアミノエチ
ルセルロースの如き陰イオン交換体はOH-型で
用いてもよく、予じめCI-型として用いてもよい
が安定性を考慮して塩型の方が好ましい。
これらの吸着体は生理食塩水で予じめ洗浄して
用いる。本発明の実施において前記吸着体をポリ
プロピレン製等の硬質プラスチツクでできたカラ
ムに25ミクロン程度のオープニングを有するメツ
シユ、例えばナイロンメツシユで支持する吸着体
のカラムへの充填は、生理食塩水に懸濁した吸着
体を流しこみ、場合により加圧して２〜６ml／１
ｇの割でつめる。吸着体の量は、血液100mlに対
して10〜50mlの範囲である。吸着体に血液を通し
たあとの洗浄は、赤血球の回収率をあげるために
行なつた方がよく、洗浄液は生理食塩水で行な
う。洗浄の生理食塩水の量は吸着体１mlに対し１
〜３mlが適当である。カラムを通過せしめる時間
は５〜120分の範囲で、流速が遅い場合は１Kg／
cm2以下の力で加圧して溶出を早めてもよい。
以下の実施例１〜５に示されているように、本
発明の方法によつてヒト全血、赤血球沈層および
哺乳動物の血液から赤血球を分画した結果、赤血
球の回収率は95％以上白血球、血小板の除去率は
99％以上という結果が得られた。回収された赤血
球を走査型電子顕微鏡で観察すると吸着体に接触
する前と全く同一の円盤状を示し、パーパート法
で浸透圧脆弱性とみると吸着体接触前後で全く変
化はなかつた。又、吸着体に接触させたものとさ
せなかつたものとを４℃で１週間保存後、アデノ
シン−トリリン酸、2.3−ジホスホグリセン酸の
定量を行なつた結果、定量値に全く差はみとめら
れなかつた。
本発明の方法を実施するための装置としては、
第１図に示すような装置があり、吸着体５を充填
し吸着体５をナイロンメツシユ４で支持したカラ
ム３に血液バツク１を連結して用いる。ヒト全血
あるいは赤血球沈層等の血液製剤は中空針７から
導管２を通つて吸着体５が充填されたカラム３に
導かれ白血球・血小板は吸着体５に付着する。そ
してこの吸着体５に付着しない赤血球は導管２を
通つて血液バツク１に回収される。また、この装
置はオ吸着体トクレーブで115℃15分処理して無
菌化が可能である。この加熱処理で変化をうける
ものは陰イオン交換体のジエチルアミノエチルセ
ルロースで他のセルロースはこの処理で何ら影響
をうけない。
以上説明したように、本発明の装置は低廉な吸
着剤を用いて、ヒト全血あるいは赤血球沈層から
組織抗原を含む白血球・血小板が完全に除かれた
成分輸血用の赤血球の調製が簡単、かつ経済的に
できるようにし、臨床検査用の純粋な赤血球の調
製を容易にする等の効果を生ぜしめるものであ
る。
以下、実施例をもつて本発明を具体的に説明す
る。
実施例 １
KC−フロツクＷ−50（Ｓ）（山陽国策パルプ株
式会社製）0.5ｇを生理食塩水約５mlに懸濁して、
これを内容積10mlの25ミクロンのオープニングを
有するナイロンメツシユ２枚をしいたポリプロピ
レン製カラムにつとめる。加圧して吸着体の容積
を2.5mlにする。ヘパリン10IU／mlを含むヒト新
鮮全血6.0mlを流す。時更に生理食塩水2.0mlを流
し合計約８mlの画分を得る。所用時間約30分。吸
着体を含まないカラムに血液を流し（ブランク）
同様に処理したもの、および全血６mlに生理食塩
水２mlを加えたものを同時に血球数を比較した。
The present invention uses leukocytes from blood. The present invention relates to a device for adsorbing and removing platelets. In particular, it relates to a leukocyte and platelet removal device for obtaining leukocyte and platelet-free red blood cells for blood component transfusions or biochemical tests. In the past, whole blood was often used in blood transfusions, but recently, with advances in medical care, treatment methods in which only the necessary components are transfused, called so-called component transfusions, are being promoted both domestically and internationally. However, red blood cell transfusions are not always carried out frequently because there is no excellent method for completely removing leukocytes containing HL-A antigens and platelets containing platelet antigens. Also, in a biochemical function test of red blood cells, the presence of other blood cell components does not yield good results. Known techniques for fractionating red blood cells for the purpose of blood transfusion include the following methods. (1) centrifugation, (2) saline washing, (3) erythrocyte sedimentation with dextran or HES, (4) nylon column passage, (5) preparation of thawed red blood cell suspension. Component Therapy, published by American Association of Blood Banks, Twenty-Eights Century Press.
USA (Blood Component Therapy,
American Association oof Blood Banks,
Twentieth Century Press U.SA), pp.9-13
1969; Japanese Red Cross Blood Center Business Standards Showa
1950: Handbook of the Era of Blood Cell Component Transfusion, published by Osaka Red Cross Center, 1975], in which (3) is actually performed as leukocyte-removed red blood cells "Nisseki", but both involve the recovery of red blood cells, white blood cells, and platelets. However, the removal of this is not satisfactory. In addition, as described in (4) above, a method using cotton and cotton thread is used to pack an adsorbent into a column [Fleming, Prefecture Journal].
of Experimental Bathology (British
Journal of Experimental Pathalogy), Volume 7, 281
Page, 1926; Diepenhorst
et al., Vox Sang., vol. 23
308-320, 1972], Method using Danelon fiber [Langfelder et al., Vox Sang., Vol. 19, p. 57,
1970], but the separation of lymphocytes from platelets and white blood cells is not good, and the amount of adsorbent is large compared to the amount of blood, making it difficult to recover red blood cells sufficiently. Nakao et al. [Nature New Biology, vol. 246, p. 94, 1973
[2007] purified red blood cells from heparinized whole blood using cation-exchange cellulose or cation-exchange Cephadex, but ion exchangers are expensive, magnesium ions are not readily available, and blood volume is limited. It has drawbacks such as a large amount of adsorbent, making it impractical. On the other hand, Wright (The Lancet, Vol. 1, p. 4, 1926) found that leukocytes were adsorbed to filter paper, but Garvin (Journal of Experimental Medicine)
Medicine), Vol. 114, p. 51, 1961] states that the adsorption to filter paper is not very large. As a result of intensive research in view of the above circumstances, the inventor of the present invention has found that leukocytes and platelets from human whole blood, erythrocyte sedimentation layer, and mammalian blood are almost completely attached to cellulose powder, crystalline cellulose, and anion-exchanged cellulose. The present invention was completed by successfully recovering red blood cells with high purity and high yield. The leukocyte and platelet removal device of the present invention includes a column and an adsorbent filled in the column, the column having a blood inlet and a blood outlet, and the adsorbent having a blood inlet and a blood outlet. The column is made of at least one of cellulose powder, crystalline cellulose, and anion-exchanged cellulose, and the column is further provided with a mesh that supports the adsorbent. The blood used in the practice of the present invention includes human fresh blood to which an appropriate anticoagulant such as heparin, ACD, and CPD has been added, and erythrocyte sediment layer (Japan Red Cross), but is not necessarily limited to these. Any preparation containing suspended red blood cells will work. When using an erythrocyte sedimentation layer, add 1/3 to 1/2 volume of physiological saline or isotonic buffer. In addition, adsorbents used in the practice of the present invention include cellulose powder, crystalline cellulose, and anion exchange cellulose, such as KC floc manufactured by Sanyo Kokusaku Pulp, filter paper powder manufactured by Toyo Roshi, Avicel manufactured by Asahi Kasei, and diethylaminoethyl cellulose. be able to. An anion exchanger such as diethylaminoethyl cellulose may be used in the OH - form or may be used in the CI - form in advance, but in consideration of stability, the salt form is preferred. These adsorbents are washed in advance with physiological saline before use. In the practice of the present invention, the adsorbent is supported in a column made of hard plastic such as polypropylene with a mesh having an opening of about 25 microns, for example, a nylon mesh, and the adsorbent is suspended in physiological saline. Pour the cloudy adsorbent and apply pressure if necessary to give a volume of 2 to 6 ml/1.
Fill by g. The amount of adsorbent ranges from 10 to 50 ml per 100 ml of blood. Washing after passing blood through the adsorbent should be done to increase the recovery rate of red blood cells, and the washing solution should be physiological saline. The amount of physiological saline for washing is 1 for 1 ml of adsorbent.
~3 ml is appropriate. The time to pass through the column is in the range of 5 to 120 minutes, and if the flow rate is slow, the flow rate is 1 kg/
Elution may be accelerated by applying pressure with a force of cm 2 or less. As shown in Examples 1 to 5 below, as a result of fractionating red blood cells from human whole blood, erythrocyte sediment layer, and mammalian blood by the method of the present invention, the recovery rate of red blood cells was over 95%. The removal rate of white blood cells and platelets is
A result of over 99% was obtained. When the recovered red blood cells were observed under a scanning electron microscope, they showed exactly the same disk shape as before contact with the adsorbent, and when viewed by Perpart's method, there was no change in osmotic fragility before and after contact with the adsorbent. In addition, after one week of storage at 4°C with and without contact with the adsorbent, adenosine triphosphate and 2,3-diphosphoglycenic acid were quantified, and no difference was observed in the quantitative values. Ta. The apparatus for carrying out the method of the present invention includes:
There is an apparatus as shown in FIG. 1, in which a blood bag 1 is connected to a column 3 filled with an adsorbent 5 and supported by a nylon mesh 4. Blood products such as human whole blood or an erythrocyte sediment layer are guided from a hollow needle 7 through a conduit 2 to a column 3 filled with an adsorbent 5, and white blood cells and platelets adhere to the adsorbent 5. Red blood cells that do not adhere to the adsorbent 5 are collected into the blood bag 1 through the conduit 2. Additionally, this device can be sterilized by treatment at 115°C for 15 minutes in an adsorbent toclave. The only substance that is changed by this heat treatment is the anion exchanger diethylaminoethylcellulose, and other celluloses are not affected at all by this treatment. As explained above, the device of the present invention uses an inexpensive adsorbent to easily prepare red blood cells for component transfusion from which white blood cells and platelets containing tissue antigens have been completely removed from human whole blood or red blood cell sediment layer. It also makes it economical and produces effects such as facilitating the preparation of pure red blood cells for clinical tests. The present invention will be specifically described below with reference to Examples. Example 1 0.5 g of KC-Flock W-50 (S) (manufactured by Sanyo Kokusaku Pulp Co., Ltd.) was suspended in about 5 ml of physiological saline.
This was applied to a polypropylene column with an internal volume of 10 ml and two sheets of nylon mesh having an opening of 25 microns. Apply pressure to bring the volume of the adsorbent to 2.5 ml. Run 6.0 ml of fresh human whole blood containing 10 IU/ml of heparin. Then, 2.0 ml of physiological saline was added to obtain a total fraction of about 8 ml. It takes about 30 minutes. Pour blood into a column containing no adsorbent (blank)
Blood cell counts were simultaneously compared between samples treated in the same manner and samples prepared by adding 2 ml of physiological saline to 6 ml of whole blood.
【表】
実施例 ２
KC−フロツクＷ−50（Ｓ）0.5ｇを実施例１と
同様にカラムにつめ、赤血球沈層（日赤）4.0ml
に生理食塩水2.0mlを加えて流す。以上実施例１
と同様に処理し、血球カウントした。[Table] Example 2 Fill a column with 0.5 g of KC-Flock W-50 (S) in the same manner as in Example 1, and add 4.0 ml of red blood cell sediment layer (Nisseki).
Add 2.0ml of physiological saline and drain. Above example 1
The cells were treated in the same manner as above, and blood cells were counted.
【表】
実施例 ３
KCフロツクＷ−50（Ｓ）0.5ｇを実施例１と同
様にカラムにつめ兎新鮮血にヘパリン10IU／ml
を加えたもの6.0mlを流す。以下実施例１と同様
に処理し、血球をカウントした。[Table] Example 3 0.5 g of KC Flock W-50 (S) was packed into a column in the same manner as in Example 1, and 10 IU/ml of heparin was added to fresh rabbit blood.
Pour 6.0ml of the mixture. Thereafter, the same treatment as in Example 1 was carried out, and blood cells were counted.
【表】
実施例 ４
アビセルPH101（旭化成工業株式会社製）0.5ｇ
を生理食塩水約５mlに懸濁して、実施例１と同様
にカラムにつめ吸着体の容積を1.0mlとする。こ
れに赤血球沈層（日赤）4.0mlに生理食塩水2.0ml
を加えて流す。以下実施例１と同様に処理し血球
をカウントした。[Table] Example 4 Avicel PH101 (manufactured by Asahi Kasei Corporation) 0.5g
was suspended in about 5 ml of physiological saline, and packed into a column in the same manner as in Example 1, so that the volume of the adsorbent was 1.0 ml. Add to this 4.0 ml of erythrocyte sedimentation layer (Nisseki) and 2.0 ml of physiological saline.
Add and drain. Thereafter, the cells were treated in the same manner as in Example 1, and blood cells were counted.
【表】
実施例 ５
ジエチルアミノエチルセルロース（CI-型）
（東京化成工業株式会社製をCI-型として精製乾
燥したもの）0.5ｇを生理食塩水約５mlに懸濁し
実施例１と同様にカラムにつめ、赤血球沈層（日
赤）4.0mlに生理食塩水2.0mlを加えて流す。以下
実施例１と同様に処理し血球をカウントした。[Table] Example 5 Diethylaminoethylcellulose (CI - type)
(purified and dried as CI - type manufactured by Tokyo Kasei Kogyo Co., Ltd.) 0.5g was suspended in about 5ml of physiological saline and packed in a column in the same manner as in Example 1, and 4.0ml of erythrocyte sedimentation layer (Nisseki) was added with physiological saline. Add 2.0ml and drain. Thereafter, the cells were treated in the same manner as in Example 1, and blood cells were counted.
第１図は本発明の装置の１実施例を示す図であ
る。
１…血液バツク、２…導管、３…カラム、４…
ナイロンメツシユ、５…吸着体、６…分岐管、７
…中空針。
FIG. 1 is a diagram showing one embodiment of the apparatus of the present invention. 1... Blood bag, 2... Conduit, 3... Column, 4...
Nylon mesh, 5...adsorbent, 6...branch pipe, 7
...Hollow needle.
Claims (1)
する白血球および血小板除去装置であつて、前記
カラムは血液流入口と血液流出口を有し、前記吸
着体はセルロース粉末、結晶セルロース、陰イオ
ン交換セルロースのうち少なくともひとつからな
り、さらに、前記カラム内には該吸着体を支持す
るメツシユが設けられていることを特徴とする白
血球および血小板除去装置。1. A leukocyte and platelet removal device having a column and an adsorbent packed in the column, wherein the column has a blood inlet and a blood outlet, and the adsorbent contains cellulose powder, crystalline cellulose, anion exchanger, etc. A leukocyte and platelet removal device comprising at least one cellulose, and further comprising a mesh for supporting the adsorbent in the column.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58204243A JPS5995051A (en) | 1983-10-31 | 1983-10-31 | Apparatus for fractionating and purifying blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58204243A JPS5995051A (en) | 1983-10-31 | 1983-10-31 | Apparatus for fractionating and purifying blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5995051A JPS5995051A (en) | 1984-05-31 |
| JPH0326170B2 true JPH0326170B2 (en) | 1991-04-10 |
Family
ID=16487216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58204243A Granted JPS5995051A (en) | 1983-10-31 | 1983-10-31 | Apparatus for fractionating and purifying blood |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5995051A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2957306B1 (en) | 2013-02-12 | 2019-01-02 | Toray Industries, Inc. | Blood purification column |
-
1983
- 1983-10-31 JP JP58204243A patent/JPS5995051A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5995051A (en) | 1984-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6063624A (en) | Platelet suspensions and methods for resuspending platelets | |
| Kikugawa et al. | Filter columns for preparation of leukocyte-poor blood for transfusion | |
| US4130642A (en) | Method of separating blood cells components | |
| US6352642B1 (en) | Leukocyte-removing filter material | |
| US4663058A (en) | Process for continuous separation of leukocyte/platelet-enriched fraction from whole blood | |
| US4765899A (en) | Apparatus for continuous separation of leukocyte/platelet-enriched fraction from whole blood | |
| US3876775A (en) | Stable intravenously injectable plasma protein free from hypotensive effects and process for its production | |
| JPH01320064A (en) | Blood component separating system | |
| EP0623045B1 (en) | Method for filtering a body fluid using rinse chamber bag | |
| JPH0326170B2 (en) | ||
| JPS5929563B2 (en) | Red blood cell fractionation and purification method | |
| Ma et al. | Comparison of two methods for concentrating stem cells for cryopreservation and transplantation | |
| CA2000717A1 (en) | Process for producing hemoglobin concentrate | |
| JPS5854130B2 (en) | Leukocyte separation method | |
| JP3065728B2 (en) | Mononuclear cell separation tube and mononuclear cell separation method | |
| DE4019114A1 (en) | Filter for selective leucocyte removal from blood etc. - has packing material of plant cell walls, not altering concn., function etc. of erythrocytes | |
| JPS5854131B2 (en) | How to isolate leukocytes | |
| Swank et al. | Platelet-Leukocyte Emboli-Origins, Effects & Treatment | |
| JPS5854126B2 (en) | Leukocyte separation material | |
| JP3938973B2 (en) | Cell separation method | |
| JPH09168585A (en) | Blood bag system | |
| JP4043094B2 (en) | Cell separator | |
| Hogan et al. | A simple method for preparing neocyte‐enriched leukocyte‐poor blood for transfusion‐dependent patients | |
| JPS5936886B2 (en) | How to isolate white blood cells | |
| JP4402236B2 (en) | Lipoprotein adsorption removal method |